vs
Side-by-side financial comparison of Hologic (HOLX) and Ovintiv Inc. (OVV). Click either name above to swap in a different company.
Ovintiv Inc. is the larger business by last-quarter revenue ($2.1B vs $1.0B, roughly 2.0× Hologic). Ovintiv Inc. runs the higher net margin — 46.1% vs 17.1%, a 29.0% gap on every dollar of revenue. On growth, Hologic posted the faster year-over-year revenue change (2.5% vs -6.0%). Ovintiv Inc. produced more free cash flow last quarter ($489.0M vs $215.2M). Over the past eight quarters, Hologic's revenue compounded faster (1.5% CAGR vs -7.2%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Ovintiv Inc. is a U.S. petroleum company based in Denver. The company was formed in 2020 through a restructuring of its Canadian predecessor, Encana.
HOLX vs OVV — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $2.1B |
| Net Profit | $179.1M | $946.0M |
| Gross Margin | 56.0% | — |
| Operating Margin | 22.6% | 21.2% |
| Net Margin | 17.1% | 46.1% |
| Revenue YoY | 2.5% | -6.0% |
| Net Profit YoY | -10.9% | 1676.7% |
| EPS (diluted) | $0.79 | $3.64 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $2.1B | ||
| Q3 25 | $1.0B | $2.0B | ||
| Q2 25 | $1.0B | $2.2B | ||
| Q1 25 | $1.0B | $2.4B | ||
| Q4 24 | $1.0B | $2.2B | ||
| Q3 24 | $988.0M | $2.2B | ||
| Q2 24 | $1.0B | $2.2B | ||
| Q1 24 | $1.0B | $2.4B |
| Q4 25 | $179.1M | $946.0M | ||
| Q3 25 | $187.2M | $148.0M | ||
| Q2 25 | $194.9M | $307.0M | ||
| Q1 25 | $-17.4M | $-159.0M | ||
| Q4 24 | $201.0M | $-60.0M | ||
| Q3 24 | $178.6M | $507.0M | ||
| Q2 24 | $194.5M | $340.0M | ||
| Q1 24 | $169.9M | $338.0M |
| Q4 25 | 56.0% | — | ||
| Q3 25 | 55.6% | — | ||
| Q2 25 | 56.3% | — | ||
| Q1 25 | 37.5% | — | ||
| Q4 24 | 56.8% | — | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 55.4% | — | ||
| Q1 24 | 53.3% | — |
| Q4 25 | 22.6% | 21.2% | ||
| Q3 25 | 22.6% | 13.5% | ||
| Q2 25 | 24.9% | 23.1% | ||
| Q1 25 | -0.7% | -3.7% | ||
| Q4 24 | 22.5% | 0.1% | ||
| Q3 24 | 23.3% | 24.2% | ||
| Q2 24 | 24.1% | 25.4% | ||
| Q1 24 | 20.7% | 20.7% |
| Q4 25 | 17.1% | 46.1% | ||
| Q3 25 | 17.8% | 7.3% | ||
| Q2 25 | 19.0% | 13.9% | ||
| Q1 25 | -1.7% | -6.7% | ||
| Q4 24 | 19.7% | -2.7% | ||
| Q3 24 | 18.1% | 23.3% | ||
| Q2 24 | 19.2% | 15.5% | ||
| Q1 24 | 16.7% | 14.2% |
| Q4 25 | $0.79 | $3.64 | ||
| Q3 25 | $0.84 | $0.57 | ||
| Q2 25 | $0.86 | $1.18 | ||
| Q1 25 | $-0.08 | $-0.61 | ||
| Q4 24 | $0.87 | $-0.22 | ||
| Q3 24 | $0.75 | $1.92 | ||
| Q2 24 | $0.82 | $1.27 | ||
| Q1 24 | $0.72 | $1.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $280.0M |
| Total DebtLower is stronger | $2.5B | $5.2B |
| Stockholders' EquityBook value | $5.2B | $11.2B |
| Total Assets | $9.2B | $20.4B |
| Debt / EquityLower = less leverage | 0.48× | 0.46× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | $280.0M | ||
| Q3 25 | $2.2B | $25.0M | ||
| Q2 25 | $1.9B | $20.0M | ||
| Q1 25 | $1.6B | $8.0M | ||
| Q4 24 | $2.0B | $42.0M | ||
| Q3 24 | $2.3B | $9.0M | ||
| Q2 24 | $2.4B | $8.0M | ||
| Q1 24 | $2.2B | $5.0M |
| Q4 25 | $2.5B | $5.2B | ||
| Q3 25 | $2.5B | $5.2B | ||
| Q2 25 | $2.5B | $5.3B | ||
| Q1 25 | $2.5B | $5.5B | ||
| Q4 24 | $2.5B | $5.5B | ||
| Q3 24 | $2.5B | $5.9B | ||
| Q2 24 | $2.5B | $6.1B | ||
| Q1 24 | $2.6B | $6.2B |
| Q4 25 | $5.2B | $11.2B | ||
| Q3 25 | $5.0B | $10.2B | ||
| Q2 25 | $4.8B | $10.4B | ||
| Q1 25 | $4.6B | $10.1B | ||
| Q4 24 | $4.8B | $10.3B | ||
| Q3 24 | $5.1B | $10.7B | ||
| Q2 24 | $5.0B | $10.3B | ||
| Q1 24 | $4.8B | $10.3B |
| Q4 25 | $9.2B | $20.4B | ||
| Q3 25 | $9.0B | $19.4B | ||
| Q2 25 | $8.8B | $19.7B | ||
| Q1 25 | $8.5B | $19.6B | ||
| Q4 24 | $8.7B | $19.3B | ||
| Q3 24 | $9.2B | $19.9B | ||
| Q2 24 | $8.9B | $19.8B | ||
| Q1 24 | $8.7B | $19.8B |
| Q4 25 | 0.48× | 0.46× | ||
| Q3 25 | 0.50× | 0.51× | ||
| Q2 25 | 0.52× | 0.51× | ||
| Q1 25 | 0.55× | 0.55× | ||
| Q4 24 | 0.53× | 0.53× | ||
| Q3 24 | 0.49× | 0.55× | ||
| Q2 24 | 0.51× | 0.59× | ||
| Q1 24 | 0.53× | 0.60× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $954.0M |
| Free Cash FlowOCF − Capex | $215.2M | $489.0M |
| FCF MarginFCF / Revenue | 20.5% | 23.8% |
| Capex IntensityCapex / Revenue | 1.4% | 22.6% |
| Cash ConversionOCF / Net Profit | 1.28× | 1.01× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $1.5B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | $954.0M | ||
| Q3 25 | $355.1M | $812.0M | ||
| Q2 25 | $343.3M | $1.0B | ||
| Q1 25 | $169.4M | $873.0M | ||
| Q4 24 | $189.3M | $1.0B | ||
| Q3 24 | $367.0M | $1.0B | ||
| Q2 24 | $405.8M | $1.0B | ||
| Q1 24 | $292.4M | $659.0M |
| Q4 25 | $215.2M | $489.0M | ||
| Q3 25 | $341.4M | $268.0M | ||
| Q2 25 | $330.5M | $492.0M | ||
| Q1 25 | $153.9M | $256.0M | ||
| Q4 24 | $172.5M | $468.0M | ||
| Q3 24 | $350.6M | $484.0M | ||
| Q2 24 | $385.3M | $398.0M | ||
| Q1 24 | $279.6M | $68.0M |
| Q4 25 | 20.5% | 23.8% | ||
| Q3 25 | 32.5% | 13.3% | ||
| Q2 25 | 32.3% | 22.2% | ||
| Q1 25 | 15.3% | 10.8% | ||
| Q4 24 | 16.9% | 21.4% | ||
| Q3 24 | 35.5% | 22.2% | ||
| Q2 24 | 38.1% | 18.1% | ||
| Q1 24 | 27.5% | 2.8% |
| Q4 25 | 1.4% | 22.6% | ||
| Q3 25 | 1.3% | 26.9% | ||
| Q2 25 | 1.3% | 23.5% | ||
| Q1 25 | 1.5% | 26.0% | ||
| Q4 24 | 1.6% | 25.3% | ||
| Q3 24 | 1.7% | 24.7% | ||
| Q2 24 | 2.0% | 28.4% | ||
| Q1 24 | 1.3% | 24.8% |
| Q4 25 | 1.28× | 1.01× | ||
| Q3 25 | 1.90× | 5.49× | ||
| Q2 25 | 1.76× | 3.30× | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.05× | 2.02× | ||
| Q2 24 | 2.09× | 3.00× | ||
| Q1 24 | 1.72× | 1.95× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
OVV
| Product And Service Revenue | $1.7B | 84% |
| Sales Of Purchased Product | $338.0M | 16% |
